Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effects of Active VItamin D on Left Atrial Volume Index (AVID-LAVI)

This study has been withdrawn prior to enrollment.
(Investigator decided not to pursue.)
Sponsor:
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01630408
First received: June 26, 2012
Last updated: August 15, 2013
Last verified: August 2013
  Purpose

This is a pilot feasibility study to determine the effects of an activated vitamin D compound (paricalcitol) on heart structure (size) and function (ability to relax) in patients with normal kidney function and a form of heart failure known as HFPEF (heart failure and preserved ejection fraction). This study will also examine heart failure-related hospitalizations and changes in cardiac-stretch and biological markers that are believed to change along with heart size. Patients in this pilot study will be treated for a period of 48 weeks with paricalcitol at a dose previously approved by FDA (1 mcg per day) and followed-up for 4 weeks after treatment is completed.


Condition Intervention
Heart Failure
Drug: Paricalcitol

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of the Effects of Active VItamin D on Left Atrial Volume Index in Patients With Heart Failure and Preserved Ejection Fraction

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Change in left atrial volume index (LAVI) by transthoracic echocardiography. [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
    The analysis will include all patients with at least two echocardiographic studies (baseline and one follow up). The primary endpoint will be determined upon completion of the study (ie, when all enrolled patients have been treated for up to 48 weeks with study medication).


Secondary Outcome Measures:
  • Number of and time-to-first heart failure-related hospitalizations [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Overall cardiac and non-cardiac mortality rates [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • Changes in biological, inflammatory, LVH and strain biomarkers that have been linked to cardiovascular disease. [ Time Frame: Baseline and 48 weeks ] [ Designated as safety issue: No ]
    High-sensitivity troponin-T, NT-proBNP, high-sensitivity C-reactive protein, propeptide procollagen type I, ST-2, Galectin-3, GDF-15 and osteoprotegerin

  • Changes in standard mineral metabolite parameters (calcium, phosphorus, calcium-phosphate-product and PTH) [ Time Frame: Baseline and 48 weeks ] [ Designated as safety issue: No ]
  • Changes in self-reported Patient Global Assessment [ Time Frame: Baseline and 48 weeks ] [ Designated as safety issue: No ]
  • Change in diastolic function parameters (including E, A, IVRT, DT) [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
  • Change in tissue doppler parameters (including Ea, Aa) [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
  • Change in pulmonary venous inflow (including S, D, a reversal) [ Time Frame: Baseline to Week 48 ] [ Designated as safety issue: No ]
  • Change in cardiac ejection fraction [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
  • Change in end-diastolic and end-systolic left ventricular internal dimension [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: March 2014
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paricalcitol
Paricalcitol oral capsules (1 mcg per day for 48 weeks)
Drug: Paricalcitol
Paricalcitol oral capsules 1 mcg/day for 48 weeks
Other Name: Zemplar®

Detailed Description:

Heart failure (HF) is among the top ten causes of hospitalizations in the US. It is estimated that ~40-50% of patients with HF have preserved ejection fraction (EF). Patients with heart failure and preserved ejection fraction (HFPEF) have normal systolic function, but impaired cardiac relaxation. The main causes of HFPEF include left-ventricular hypertrophy (LVH) and hypertension, hypertrophic cardiomyopathy, aortic stenosis with a normal EF, coronary artery disease and restrictive cardiomyopathies.

Only a few small clinical trials have tested therapeutic interventions in patients with HFPEF, producing either small or negative effects. Relatively few drugs have effects on cardiac relaxation and are not candidates for chronic use, as they may have significant side effect profiles and/or are inconvenient to administer. Paricalcitol, an FDA-approved activated form of vitamin D, has been shown to slow LVH progression and improve parameters associated with diastolic function in animal models (see refs). Treatment with paricalcitol has also been associated with decreased cardiovascular morbidity and mortality in a historical cohort study of patients with end-stage renal disease (see refs).

This is a single-center, single-arm, pilot study in 20 patients with HFPEF and normal renal function on stable medical therapy to evaluate the effects of paricalcitol on cardiac structure and function.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Sign informed consent.
  • Willing and able to adhere to all study-related procedures, including study medication regimen.
  • ≥ 18 years old.
  • Previous clinical diagnosis of heart failure with preserved ejection fraction: NYHA Class II-IV.
  • Satisfy these echocardiographic criteria within the last year: Left ventricular ejection fraction ≥ 50%, cardiac magnetic resonance or ventriculogram; Left atrial size ≥ 4 cm in long axis or > 5.2 cm in four chamber length; Septal wall thickness > 1.2 cm (females) or 1.3 cm (males); Doppler evidence of moderate or severe diastolic dysfunction (≥ Grade II) by transmitral inflow, pulmonary venous flow, color M-mode and/or tissue Doppler (per European Society of Cardiology guidelines).
  • Experienced ≥ 1 of the following in last 12 months: Hospitalization for acute heart failure (primary diagnosis); Long term treatment with loop diuretic; Mean pulmonary capillary wedge pressure ≥ 16 mm Hg at catheterization for dyspnea; Left ventricular end diastolic pressure (LVEDP) ≥ 19 mm Hg at catheterization for dyspnea; Acute treatment with intravenous loop diuretic or hemofiltration.
  • On stable medical therapy in last 30 days before study entry (defined as no change in angiotensin converting enzyme inhibitors [ACEI], angiotensin receptor blockers, aldosterone inhibitors, beta-blockers or calcium channel blockers.
  • Satisfy these criteria at initial lab screening: Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min; Corrected serum Ca 8.0-10.0 mg/dL (2.0-2.5 mmol/L); Phos ≤ 5.2 mg/dL (1.68 mmol/L); Serum albumin ≥ 3.0 g/dL (30 g/L);
  • Negative serum pregnancy test for females of childbearing potential (within 2 weeks of starting study treatment).
  • Women of childbearing potential must be practicing barrier/oral contraception during study-related treatment, or be surgically sterile or one year post-menopausal, be non-nursing and non-pregnant.

Exclusion Criteria:

  • Taking > 1,000 IU of vitamin D preparation daily within last 30 days.
  • Received activated vitamin D preparation including paricalcitol (Zemplar®), doxercalciferol (Hectorol®) or calcitriol (Rocalctrol®, Calcijex®) within last 90 days prior to study entry.
  • History of nephrolithiasis.
  • Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg at Screening; confirmed by repeat).
  • Secondary hypertension (i.e. renal artery stenosis, primary aldosteronism or pheochromocytoma).
  • Severe hepatic impairment.
  • Use of known inhibitors (ie, ketoconazole) or inducers (ie, carbamazepine) of cytochrome P450 3A (CYP3A) within 2 weeks prior to taking study drug.
  • HIV positive.
  • Condition with prognosis < 1 year at study entry other than heart failure.
  • Significant valvular disease defined as moderate or severe aortic or mitral stenosis, mitral or aortic regurgitation.
  • Infiltrative cardiac disease (sarcoid, amyloid, hemochromatosis, lymphoma, etc.).
  • Arrhythmogenic right ventricular cardiomyopathy.
  • Active myocarditis.
  • Constrictive or restrictive pericarditis.
  • Acute coronary artery disease symptoms defined as emergency department visit or hospital admission with unstable angina, ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 90 days before study entry.
  • Poor echocardiographic windows.
  • Current active treatment in another investigational study or participation in another investigational study within 1 month before screening.
  • Active malignancies except in situ carcinoma of the cervix, localized squamous or basal cell carcinoma of skin.
  • Other serious concurrent or recent medical or psychiatric condition which, in Investigator's opinion, makes the patient unsuitable for participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01630408

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 01886
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Hector Tamez, MD, MPH Massachusetts General Hospital
Principal Investigator: Ravi Thadhani, MD, MPH Massachusetts General Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Ravi Thadhani, Director of Clinical Research in Nephrology, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01630408     History of Changes
Other Study ID Numbers: AVID-LAVI
Study First Received: June 26, 2012
Last Updated: August 15, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Preserved ejection fraction
Left ventricular hypertrophy
Activated vitamin D
Cardiac lusitropic effect
Hospitalizations

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Vitamin D
Vitamins
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 24, 2014